Funder
Ministry of Education, Taiwan
Ministry of Science and Technology, Taiwan
Publisher
Springer Science and Business Media LLC
Reference85 articles.
1. Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 2014;20(8):2072–2079
2. Hsu C, Cheng AL. Clinical and preclinical perspectives on mechanisms of sorafenib resistance in hepatocellular carcinoma. In: Villanueva A, editor. Resistance to molecular therapies for hepatocellular carcinoma. Switzerland: Springer; 2017
3. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163–1173
4. Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389:56–66
5. Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. E Engl J Med 2018;379(1):54–63
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献